Mark Olivier
Pfizer
7 Papers
25 Citations
Mark Olivier is an academic researcher from Pfizer. The author has contributed to research in topics: Catalysis & Heck reaction. The author has an hindex of 6, co-authored 7 publications.
Chat about Author
Papers
Commercial Route Research and Development for SGLT2 Inhibitor Candidate Ertugliflozin
Paul Bowles,Steven J. Brenek,Stephane Caron,Nga M. Do,Michele T. Drexler,Shengquan Duan,Pascal Dube,Eric C. Hansen,Brian P. Jones,Kris N. Jones,Tomislav A. Ljubicic,Teresa W. Makowski,Jason Mustakis,Jade D. Nelson,Mark Olivier,Zhihui Peng,Hahdi H. Perfect,David Place,John A. Ragan,John J. Salisbury,Corey L. Stanchina,Brian C. Vanderplas,Mark E. Webster,R. Matt Weekly +23 more
TL;DR: A practical synthesis of SGLT2 inhibitor candidate ertugliflozin has been developed for potential commercial application and high chemical purity of the API is assured through isolation of the crystalline penultimate intermediate, tetraacetate 39.
68
Palbociclib Commercial Manufacturing Process Development. Part I: Control of Regioselectivity in a Grignard-Mediated SNAr Coupling
Shengquan Duan,David Place,Hahdi H. Perfect,Nathan D. Ide,Mark T. Maloney,Karen Sutherland,Wiglesworth Kristin,Ke Wang,Mark Olivier,Fangming Kong,Kyle R. Leeman,Jon Blunt,John Draper,Marie McAuliffe,Maria M. O’Sullivan,Denis Lynch +15 more
TL;DR: In this paper, the SNAr coupling between aminopyridine 3 and chloropyrimidine 7 was studied from a synthetic and mechanistic perspective, and Grignard bases were identified as the preferred class of bases for this reaction.
44
Application of quantitative 19F and 1H NMR for reaction monitoring and in situ yield determinations for an early stage pharmaceutical candidate.
TL;DR: The application of (19)F and (1)H qNMR for reaction monitoring and in situ potency determinations will be discussed for an early stage pharmaceutical candidate with several analytical challenges.
42
Development of a Practical and Convergent Process for the Preparation of Sulopenem
Steven J. Brenek,Stephane Caron,Esmort Chisowa,Mark P. Delude,Michele T. Drexler,Marcus Ewing,Handfield Robert Eugene,Nathan D. Ide,Durgesh V. Nadkarni,Jade D. Nelson,Mark Olivier,Hahdi H. Perfect,James E. Phillips,John J. Teixeira,R. Matt Weekly,John P. Zelina +15 more
TL;DR: In this paper, a convergent process for the large-scale preparation of sulopenem was proposed, where cyclization of an oxalimide intermediate was used to provide the thiopenem core.
18
Development of a Second-Generation Process to Antibacterial Candidate Sulopenem
Steven J. Brenek,Stephane Caron,Esmort Chisowa,Roberto Colon-Cruz,Mark P. Delude,Michele T. Drexler,Handfield Robert Eugene,Brian P. Jones,Durgesh V. Nadkarni,Jade D. Nelson,Mark Olivier,R. Matt Weekly,G. C. A. Bellinger,Zinka Brkic,Neil Choi,Joe Desneves,Marcia A.-P. Lee,Wayne Pearce,Jessica K. Watson +18 more
TL;DR: In this article, the authors present the research, development, and scale-up of the broad spectrum antibacterial candidate sulopenem, where the penem ring is constructed via a modified Eschenmoser sulfide contraction sequence.
9